Secondary Outcome(s)
|
digestive vascular malformations
[Time Frame: 6 months]
|
epistaxis frequency
[Time Frame: 3 months before treatment up to 6 months from the inclusion]
|
quality of life (SF36).
[Time Frame: 3 months]
|
severity epistaxis score (ESS).
[Time Frame: 6 months.]
|
hemoglobin
[Time Frame: 3 months]
|
quality of life (SF36).
[Time Frame: 6 months]
|
To evaluate pharmacokinetics of bevacizumab dose
[Time Frame: 2 hours after the first treatment infusion]
|
adverse events
[Time Frame: up to 6 months]
|
severity epistaxis score (ESS).
[Time Frame: 3 months]
|
hemoglobin
[Time Frame: 6 months]
|
To evaluate pharmacokinetics of bevacizumab dose
[Time Frame: Before each 6 infusions]
|
duration of nosebleeds
[Time Frame: 3 months before treatment up to 6 months from the inclusion]
|